A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF)
Phase of Trial: Phase III
Latest Information Update: 12 Dec 2017
At a glance
- Drugs Omecamtiv mecarbil (Primary)
- Indications Heart failure
- Focus Registrational; Therapeutic Use
- Acronyms GALACTIC-HF
- Sponsors Amgen
- 26 Oct 2017 According to a Cytokinetics media release, the company expects continued enrollment of patients with chronic heart failure in GALACTIC-HF trial throughout 2017.
- 19 Sep 2017 According to a Cytokinetics media release, first patient ij Japan has been dosed.
- 08 Jun 2017 Planned initiation date changed from 1 Jan 2017 to 6 Jan 2017.